OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 8.89 EUR 2.42% Market Closed
Market Cap: 193.4m EUR
Have any thoughts about
OSE Immunotherapeutics SA?
Write Note

OSE Immunotherapeutics SA
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

OSE Immunotherapeutics SA
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Selling, General & Administrative
-€8m
CAGR 3-Years
3%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Selling, General & Administrative
-€145.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Selling, General & Administrative
-€21.5m
CAGR 3-Years
-7%
CAGR 5-Years
-7%
CAGR 10-Years
-20%
G
Genfit SA
PAR:GNFT
Selling, General & Administrative
-€8.9m
CAGR 3-Years
0%
CAGR 5-Years
-2%
CAGR 10-Years
-2%
Inventiva SA
PAR:IVA
Selling, General & Administrative
-€12m
CAGR 3-Years
-24%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Selling, General & Administrative
-€39.8m
CAGR 3-Years
-19%
CAGR 5-Years
-22%
CAGR 10-Years
-12%
No Stocks Found

OSE Immunotherapeutics SA
Glance View

Market Cap
193.5m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
28.25 EUR
Undervaluation 69%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's Selling, General & Administrative?
Selling, General & Administrative
-8m EUR

Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Selling, General & Administrative amounts to -8m EUR.

What is OSE Immunotherapeutics SA's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-10%

Over the last year, the Selling, General & Administrative growth was 12%. The average annual Selling, General & Administrative growth rates for OSE Immunotherapeutics SA have been 3% over the past three years , -10% over the past five years .

Back to Top